Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I guess it depends on what type of material news exists. I would think Gerald could announce a Drug delivery partnership (which is pending) ..at his leisure. But perhaps there are circumstances that warrant releasing news immediately (like lawsuits, investigations, etc).
Why release news in a bad market; sellers might dump shares into the good news (constraining any potential gains). Just a thought!
Keep in mind that the market conditions are just not favorable. I would underestimate that Gerald could wait for a better day (to release meaningful news). Just my humble opinion...pure speculation.
Answer: The company has very limited headcount and cash resources to do everything necessary. I am pleased that a decision was made to hire a 3rd party to create a powerful and meaningful write up.
Hopefully, MJF will recognize the superior nature of MANF and reward management with more grant money.
Its all about the Science!!!
For those who are naïve and don't do the proper due diligence (I have copied in Geralds direct quote regarding a future Up listing):
"The Board of Directors and Management are now working closely together to improve the corporate governance at the Board and management levels, as well as the financial controls within the Company, in order to meet the requirements of a national stock exchange listing. We expect to take concrete steps in this direction in the coming months that will be communicated to the marketplace".
Translation: it will take some time to upgrade the financial controls and corporate governance before Gerald takes us to the Nasdaq listing.
Great post RiskR. You would make an amazing detective as well.
I like that you have pushed the envelope here (if though others have deterred you from doing so). It has become a lot more clear that Novartis has some bona fide roots with AMBS (this story has all the potential to be something significant...just speculating but it feels like something substantial is going on with Novartis in one way or another).
Very intriguing Due Diligence Zoom; I am sure RiskR. will be delighted with your find. Still highly speculative; but its one scenario/possibility that seems to make some sense.
Thanks for sharing with us.
Expect a $200mm-$300mm market cap. before any decisions are made to Uplist. FYI - Gerald is (and has been) very transparent; he does not have any near term plans and/or expectations for a R/S.
We are months away before these decisions are made. I would suggest that you pick up the phone and call him directly; lets see if you get a consistent answer on this topic.
You have made an extremely inaccurate statement. Gerald told Riskreturn (at the Conference on Saturday) that he had no plans to due a Reverse split; but that he was open minded to the reality down the road.
FACT!!!!!!
I don't think today was an ideal day to release any meaningful news. I hope to think that any CEO would consider market conditions a possible constraint (make judgement as to what happens this week...not day to day).
We are sitting right on a key pivot point (at $.0650). We will need some volume to push through here.
I am a big believer that the Diagnostic division will be sold to fund the development of MANF. More importantly, I am fairly confident the Holding company was structured that way for a reason.
Eli Lilly news (Amyvid - Alzheimers imaging agent). Why is this important; perhaps Lilly will potentially consider an alliance or relationship with AMBS (as they have literally struck out obtaining reimbursement from the Govt. Medicare programs for Amyvid). Please read:
1:35AM Eli Lilly expresses disappointment in Medicare decision to deny appropriate pa1:35AM Eli Lilly expresses disappointment in Medicare decision to deny appropriate patient access to beta-amyloid imaging agents, including Amyvid (LLY) 50.50 : Eli Lilly is disappointed that the Centers for Medicare & Medicaid Services has denied patient access to beta-amyloid imaging agents, such as Amyvis. This final decision is not only contrary to expert opinion and published Appropriate Use Criteria previously recommended by the Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging, but contradicts the statutory authority CMS has over coverage determinations for diagnostics. Denying appropriate patient access is also in conflict with the administration's National Alzheimer's Project Act.
CMS participated in creating this plan aimed at developing new and innovative ways to diagnose, support and treat patients suffering from Alzheimer's Disease-yet the same agency is challenging the value of the only technology approved by the FDA for estimating beta-amyloid neuritic plaque density in the living brain, which can aid in helping doctors make a more informed diagnosis. tient access to beta-amyloid imaging agents, including Amyvid (LLY) 50.50 : Eli Lilly is disappointed that the Centers for Medicare & Medicaid Services has denied patient access to beta-amyloid imaging agents, such as Amyvis. This final decision is not only contrary to expert opinion and published Appropriate Use Criteria previously recommended by the Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging, but contradicts the statutory authority CMS has over coverage determinations for diagnostics. Denying appropriate patient access is also in conflict with the administration's National Alzheimer's Project Act.
CMS participated in creating this plan aimed at developing new and innovative ways to diagnose, support and treat patients suffering from Alzheimer's Disease-yet the same agency is challenging the value of the only technology approved by the FDA for estimating beta-amyloid neuritic plaque density in the living brain, which can aid in helping doctors make a more informed diagnosis.
They should be able too; but its clear that want to uplist within months. Specifically, Gerald said (on Saturday) he does not have plans to do a R/S (but that he was open minded to it).
If they want to uplist within months; we better hope for a very significant Partnership (or at least two). Also, there seems to be confusion as to the minimum Nasdaq listing requirements (whether its $2 or the company can satisfy other criteria). Moreover, I will have to research further...very important issue.
Great points!! Gerald was very adamant yesterday that LymPro will be the gold standard (the expectations are very high on validation results).
In his own words; he has already moved on from the validation results and what beyond in terms of commercialization going forward. Perhaps there could be a bidding war in place; and may Gerald has given BD first right of refusal (and hence; the two extra weeks to make a final decision).
GLTA!!!
Nice picture Risk...good job providing meaningful updates from the conference.
You are welcome. I am speculating like everybody else; but sometimes some things makes sense if you connect the dots (Gerald is one of the most transparent CEO's out there; its amazing what he will talk about and that he gives the time of day ..to any retail shareholder).
Riskreturn talked to him over 1 hour (pre and post conference). Very cool!!!!
As the PPS has stabilized and is now sitting above $.06 (post the latest funding news); the days of $.03 and $.04 are most likely over...this is our new bottom here.
I am extremely optimistic that the PR machine gets cranked WAY up; the PR delays (over the last week or two) were most likely because the financing deal had not been completed.
My takeaway from the Conference; and in discussing it with a person who attended...is $200mm-$300mm market cap. is Geralds near term goal (you can define timeframes any way you want)...but it was loud and clear this is a targeted threshold (as I believe any uplisting will occur once this valuation is reached...which could lead to a a possible R/S to reach a minimum $2 for a Nasdaq listing).
In my conversation with Riskreturn yesterday (post the conference); I heard and sense that the Partnership side of things will take some time (it seemed as Gerald was hinting that the terms will be much more significant and more favorable to shareholders later on.... as the Drug/Product line mature).
I am hopeful (but skeptical) that a HUGE partnership comes soon. If the 3rd parties meet Geralds terms; perhaps it can happen anyday.
ANF Diabetes is going to be very big; Geralds body language was very obvious (beaming ear to ear)....the timing of this latest funding deal (and the internal participation) ...seems to indicate something is definitely brewing.
Translation: LymPro partnership early next year (just my hunch); but I think MANF will strike gold in one of these Orphan indications (much sooner than later).
I would agree that the BD relationship might have headwinds. To me: Gerald has made some recent decisions (like multiple funding announcements) that indicate a BD JV might not be happening anytime soon.
I know Gerald has publicly stated that once the LymPro results are validated; they will get Global interest from other parties. In summary, I believe its a win win situation here; and if Gerald has to do a Partnership down the road (and even with another company); it will be at a much higher price (great news for shareholders).
Geralds latest blog update talks about the Uplisting at least four separate times. I am extremely convinced that MAJOR developments have occurred recently and/or going to progress quite well going forward.
As I can only speculate like everybody else; I sense Geralds confidence in our future PPS rise must be really significant. He is in a much better position to negotiate (with the latest funding announcements as well).
Finally, he seems to indicate that the uplisting is still months away...its going to get very interesting with how this story plays out (cant wait to see it unfold).
The reverse split issue is a real concern for me. I survived a 63 to 1 with another company (and it was only because I owned a ton of shares ) allowing me to hold enough to make money (as it eventually went higher).
Most retail shareholders (or many) could be affected in a negative way (if this reality develops). I have been extremely bullish here; but I despise a R/S (from any standpoint) More importantly, I think its an inappropriate way and is unnecessary (shareholders get screwed).
Let the good news and developments takes us up first...and perhaps a 5 for 1 (or less) is tolerable.
They just did multiple capital raises that will give them up to $8mm. Also, they are funded through 2015. Do you still think they have funding issues?
You have an extremely myopic viewpoint and analysis. You should consider being more objective analysis (that's both fair and accurate ..makes more sense).
So I am curious; as to why they don't take a position as well?
Wow! You are in Geralds backyard; go visit him at the home office. How lucky.....
Cool! I see it....perhaps he didn't send it via email this time around. Thanks for the heads up.
Have a great weekend!
Thanks! California rocks!!!! If we all make a lot of money; lets schedule a shareholder meeting somewhere out there for all.
I don't see the Chairmans blog on the company website; nor did I get an email with that update. Where is this information located exactly?
Thanks!
The $6.50 are is a pivot point. It might take some extra volume to push us through...hoping for minimally $.0670 -$.0710 pennant formation range area ..on the close.
We have an outside possibility of breaking through $.07 today. GLTA!!
Gerald is in a win/win situation. Can you imagine that several parties are interested...and he can negotiate and get the best possible terms for the shareholders.
The commercialization plans are well in tact. From the Jerry McGuire movie (with Tom Cruise); "SHOW ME THE MONEY"!!! Lol.
The groundwork has been laid for the uplisting. The good news is coming and the move higher to a new trading base. At that time, it will likely be a Partnership announcement (and then a possibility of a reasonable R/S).
The deal gives the Mgt. team excellent flexibility to drive home great partnering terms (its mostly very good here).
Be aware that the dilution is modest (only partially exercised; they have the option to exercise the warrants in full...this reality has not happened yet).
In the event the warrants are exercised in full, total proceeds to the Company resulting from this transaction will equal approximately $8 million. The additional funds raised will be used to further fund core diagnostic and therapeutic programs, as well as execute -various business development opportunities. The closing of this transaction is subject to the satisfaction of customary closing conditions and is expected to occur on or before October 1, 2013. GVC Capital LLC acted as exclusive placement agent, and Zacks & Company acted as financial advisor.
It could sell down into the low $.5 area (early on); but the good news is coming (these deals are written and completed ahead of positive developments).
You have to recognize that Mgt. has the option to exercise and convert the warrants (they did not do so in full yet; I believe they are hedging all bets if they have to go it alone).
Finally, the journey upward starts next week; I just hope the LymPro validated results are better than 90%.
A R/S is very possible; but I like that Nasdaq has lowered the listing requirements to $2 (instead of $4). In translation; it would be a less painful split basis. We have now have taken a major step for the uplisting; it wont be long before this reality happens.
My dream prediction: the company nails the BD partnership and one other MANF Orphan indication partnership (perhaps Retinosis Pigmentosis, Diabetes, etc.) ......and we catapult to closer to the $1 range. A 4 for 1 R/S (or less) would work for me (to get above $2).
Interesting read; but it still refers to a minimum stock price of $2 (but AMBS will now have the equity requirements). Lingering question; will a R/S still happen?
Under the new NasdaqCM requirements, a stock can qualify for listing if it closes at $3 or above for at least five consecutive business days prior to approval. The five-day requirement is in place to reduce the risk of price manipulation aimed at allowing a security to qualify for listing. In addition to the $3 share price requirement, the company must meet the following requirements:
?Stockholders’ equity of at least $5 million
?Market value of publicly held shares of at least $15 million
?Two years of operating history
Or:
?Net income from continuing operations of $750,000 in the most recently completed fiscal year or in two of the three most recently completed fiscal years
?Stockholders’ equity of at least $4 million
?Market value of publicly held shares of at least $5 million.
Securities with a $2 minimum closing price for five consecutive business days prior to the approval can also qualify for listing on the NasdaqCM if they meet the Market Value of Listed Securities Standard, which requires a market value of listed securities of at least $50 million, stockholders’ equity of at least $4 million, and a market value of publicly held shares of at least $15 million
Financing news this AM is out:
The can raise up to $8mm and will have funding now through 2015. In my opinion; they will be able to accelerate both the MANF and LymPro programs on a more aggressive basis. Overall, Jason Napodano has been looking for the cash raise that becomes a game changer for the company. Moreover, the ability to uplist (to a National exchange.. if the price trades over $.10 is an added bonus. Of course; the dilutive nature of any financing deal is a necessary evil.
Bottom line: the really good news (that is due out and coming) was held back due to the financing deals completed recently (a reason for everything). Expect the PR machine to light up next week!!!
News link:
http://finance.yahoo.com/news/amarantus-bioscience-holdings-announces-2nd-103554307.html
Follow the CEO folks! The company is very fundamentally solid...successfully completed multiple cash raises recently. The big news is coming...today was orchestrated short covering by those who need to cover at much lower prices.
We will rebound tomorrow heading into Monday news (or next week ).
By Nov. 1st...should settle and get at least between $.15-$.30 (any full blown Partnership announcement sends us closer to $.50). However, I am going with excellent progression with LymPro (and further validation that MANF works in multiple Orphan area's...so I will stay on the conservative side).
Great post!!! A Phase 2b ready compound will add additional value to our Market cap. I am guessing the wait is due to funding requirements....but once things move forward..it could add a nice incremental increase in value.
Its hard to believe that our PPS sits at less than $31mm. More importantly, the cash situation has been greatly improved and the Balance sheet looks solid.
Finally, I am awaiting the "game changer" announcement which will get us closer to a more reasonable valuation:
Top possibilities for the "Game changer" announcement:
1) LymPro validation data with Becton Dickinson (maybe a partnership as well).
2) A new Seeking Alpha investment report (due soon); an huge upward re evaluation of the projected value (could help increase the PPS this time around...much further advanced in their Drug and Diagnostic programs).
3) MANF Orphan data for Diabetes (and perhaps a possibility for a partnership with a Pharma.).
4) The new Orphan data for Retinitis Pigmentosa could be a blockbuster (its a $10 billion dollar market). I think this will be a highly successful program (and will lead to a Partnership sooner than the other programs...just because Gerald announced it was there new lead program at the Rodman and Renshaw conference).
5) A surprise factor...who knows what could be announced at anytime ..its what I really like about this company.
Exciting times ahead!!! GLTA!!!
Really nice close ...to come up from the .0630 area (trading there all day) and show a 500k bid with 5 minutes remaining...and closing right at the bottom of the Bullish flag formation (at $.0660) is a strong technical bullish validation. Dow down over 180!!
See Bullish Pennant stock chart formation:
http://stockcharts.com/school/doku.php?id=chart_school:chart_analysis:chart_patterns:flag_pennant_continu
Ooops.
The chart lows (recently) have been $.0660 to $.0670. It was not $.0770.